Startups
Focused on addressing expensive treatment of diabetes and lack of insulin access globally, rBIO is harnessing modern scientific technologies to tackle the global issue of diabetes.
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 1, 2024 | Houston startup completes testing, prepares biosimilar insulin drug for clinical trials | A Houston biotech startup is one step closer to releasing its marquee drug for the global insulin market, which is projected to break the $90 billion threshold by 2029. rBIO says it recently completed testing of the properties of R-biolin, ... |
| Jan 28, 2024 | Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking | Inflation remains a top consumer gripe, but the higher cost of milk and eggs is negligible when compared to insulin. Spending on insulin has tripled in the past decade, topping $22 billion in 2022, according to research from the American Di... |
| Breaking: Plastic Degradation And Synthetic Biology Company Secures $10.5 Million | Breaking, a plastic degradation and synthetic biology company, launched at Colossal Biosciences based on a core discovery out of the Wyss Institute for Biologically Inspired Engineering at Harvard University. Breaking also announced it laun... |
Reviews 0
FAQ about rbio.com
What has the press written about rbio.com?
Parsers VC has collected 4 articles mentioning rbio.com, among them “Houston startup completes testing, prepares biosimilar insulin drug for clinical trials” (Feb 1, 2024) and “Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking” (Jan 28, 2024).
Is rbio.com still active?
Yes, rbio.com is active; its latest activity on Parsers VC dates from Aug 12, 2024.